ABSTRACT
Peritoneal sarcomatosis is a rare malignant disease with a poor prognosis, secondary to peritoneal dissemination of abdominopelvic soft tissue sarcomas. Its rarity, together with the characteristic histological heterogeneity and the historically poor response to systemic treatments, has prevented the establishment of widely accepted treatment criteria with curative intent. In this sense, radical cytoreductive surgery (CRS) with peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC), widely used in peritoneal carcinomatosis with excellent results, have not had the same evolutionary development in patients with peritoneal sarcomatosis. A multidisciplinary working group of experts in sarcomas and peritoneal oncological surgery established a series of recommendations based on current scientific evidence for the management of peritoneal sarcomatosis, taking into account the different histological subgroups of abdominopelvic sarcomas that can cause it depending on their origin: retroperitoneal sarcomas, uterine sarcomas, and visceral/peritoneal sarcomas of GIST (gastrointestinal stromal tumor) and non-GIST origin. This article shows the results of sarcoma experts' voting on the recommendations presented during the I Ibero-American Consensus on the Management of Peritoneal Sarcomatosis, which took place during the recent celebration of the III Hispanic-Portuguese Meeting for Updates on the Treatment of Sarcomas.
ABSTRACT
Intestinal mucormycosis is a rare manifestation of the Mucor fungus, associated with high mortality and typically found in immunocompromised patients, though it has also been described in immunocompetent individuals. The mode of acquisition is digestive. It usually presents as abdominal pain, with ischemia and intestinal perforation, and the diagnosis is often histopathological after surgical resection. We present the case of a 54-year-old female patient with recurrent acute myeloid leukemia undergoing treatment with daunorubicin-cytarabine and experiencing febrile neutropenia. She developed patchy and progressive intestinal ischemia that evolved into intestinal necrosis, which was treated with antifungal medications and surgery. Examination of the surgical specimen revealed aseptate wide hyphae with branching at right angles, suggestive of Mucor fungus. This is a rare but highly mortal pathology in which clinical, radiological, and surgical suspicion is essential for early diagnosis and treatment, thus improving the patient's prognosis.
ABSTRACT
La exenteración pélvica masculina es un procedimiento complejo con elevada morbilidad. En casos muy seleccionados, el abordaje robótico puede facilitar la disección y reducir la morbilidad gracias a la mejor visión y versatilidad de movimientos. Describimos la técnica de exenteración pélvica robótica sistematizada con DaVinci Xi y sus variantes en varones, tras haber intervenido tres casos en nuestro Centro. Describimos la colocación de trocares, material necesario, localización de minilaparotomía y secuencia de los procedimientos a realizar paso a paso. Distinguimos tres supuestos: exenteración pélvica total con amputación de recto, colostomía y urostomía; exenteración pélvica con preservación de esfínter, anastomosis colo-rectal/anal y urostomía; exenteración pélvica con amputación de recto, colostomía y reconstrucción de tracto urinario. (AU)
Male pelvic exenteration is a challenging procedure with high morbidity. In very selected cases robotic approach could make dissection easier and decrease morbidity due to a better view and higher range of movements. In this paper we describe port placement, instruments, minilaparotomy location and sequence of procedures step by step. We differentiate three situations: total pelvic exenteration with abdominoperineal resection, colostomy and urostomy; pelvic exenteration with colo-rectal/anal anastomosis and urostomy; pelvic exenteration with abdominoperineal resection, colostomy and urinary tract reconstruction. (AU)
Subject(s)
Humans , Male , Pelvic Exenteration/methods , Robotic Surgical Procedures , Proctectomy , Colostomy , Minimally Invasive Surgical ProceduresABSTRACT
Male pelvic exenteration is a challenging procedure with high morbidity. In very selected cases, the robotic approach could make dissection easier and decrease morbidity due to the better vision provided and higher range of movements. In this paper, we describe port placement, instruments, minilaparotomy location, and the stepwise sequence of these procedures. We address 3 different situations: total pelvic exenteration with abdominoperineal resection, colostomy and urostomy; pelvic exenteration with colorectal/anal anastomosis and urostomy; and pelvic exenteration with abdominoperineal resection, colostomy and urinary tract reconstruction.
Subject(s)
Pelvic Exenteration , Proctectomy , Robotic Surgical Procedures , Male , Humans , Pelvic Exenteration/methods , Robotic Surgical Procedures/methods , Retrospective Studies , Rectum/surgery , Proctectomy/methodsABSTRACT
SANT (sclerosing angiomatoid nodular transformation) tumor is a rare splenic tumor of unknown etiology and vascular lineage, first described in 2004. Most cases are asymptomatic, although cases of anemia or abdominal pain in association with growth have been described. Spontaneous ruptures have not been described. Radiologically it presents a radial pattern with centripetal filling in dynamic MRI, being a characteristic feature, but not pathognomonic. It may present hypermetabolism in PET-CT. Its incidence is increasing since its description as an independent clinical and histopathological entity, especially in the oncological patients follow-up. Due to its radiological resemblance to metastatic lesions and its growth despite being a vascular lesion, splenectomy is indicated following the principles of oncologic surgery until a definitive diagnosis is made. It presents a benign behavior, requiring neither treatment nor specific subsequent surveillance. Two diagnosed cases of SANT are presented, as well as a review of the clinical, radiological and histopathological characteristics of this little-known splenic lesion.
ABSTRACT
OBJECTIVE: The aim is to analyze the usefulness of pre-operative COVID-19 screening to detect asymptomatic patients, the capability of our patient selection algorithm to detect patients with more advanced tumors and the results of colorectal cancer surgery managed with a multimodal approach. We propose the use of a preoperative patient selection algorithm to prioritize the surgical treatment of patients with worse oncological prognosis and lower perioperative risk in situations of health system saturation. MATERIAL AND METHODS: Prospective descriptive study including 71 patients operated on for colorectal cancer during COVID-19's high incidence period. A division was made into two periods of time that were later compared with the aim of assessing whether the scale used identified those patients with lower surgical risk and higher oncological priority for their priority scheduling. RESULTS: Post-operative severe acute respiratory syndrome coronavirus 2 infection occurred in one patient (1.4%). Pre-operative polymerase chain reaction detected one asymptomatic patient (3%). Tumor stage was ≥ IIIA in 39% and node positive in 39% of patients in the first period, while 26% and 21% in the second period, respectively (p = 0.320; p = 0.179), without increasing the surgical stay or complications. Median hospital stay was 5 days. Grades III and IV morbidity were 4.4% and 1.4%. CONCLUSION: The use of an algorithm and Patient Selection Scale can detect patients with more advanced tumors to be operated before. Multimodal management/ERAS have a role in achieving short stay and low morbidity.
OBJETIVO: El retraso terapéutico derivado de la saturación del Sistema sanitario conlleva un peor pronóstico oncológico y un aumento de complicaciones en el cáncer colorrectal. Proponemos el usode un algoritmo de selección de pacientes de forma preoperatoria para priorizar el tratamiento quirúrgico de los pacientes con peor pronóstico oncológico y menor riesgo perioperatorio. MATERIAL Y MÉTODOS: Realizamos un estudio descriptivo prospectivo de 71 pacientes intervenidos por cáncer colorrectal durante el periodo de máxima incidencia por COVID. Se realizó una división en dos periodos de tiempo que fueron comparados posteriormente con el objetivo de valorar si la escala utilizada conseguía identificar aquellos pacientes con menor riesgo quirúrgico y mayor prioridad oncológica para su programación prioritaria. RESULTADOS: Utilizando la escala de priorización de pacientes (PSS) observamos que el estadio tumoral fue mayor de IIIA en un 39% de los pacientes con un 39% de ganglios positivos en un primer periodo, frente a un 26% y 21% en un segundo periodo (p = 0.320; p = 0.179) de tiempo, sin aumentar la estancia operatoria ni las complicaciones. Se realizaron dos métodos de cribado de COVID-19 en dos periodos de tiempo, detectando un 3% de pacientes asintomáticos de forma preoperatoria con PCR, y documentando un 1.4% de infección por COVID postoperatoria. CONCLUSIONES: Ante la saturación del sistema sanitario, la utilización de protocolos y algoritmos para selección de pacientes con cáncer colorrectal puede ayudar a dar preferencia quirúrgica a aquellos casos que no deben ser demorados.
Subject(s)
COVID-19 , Colorectal Neoplasms , Colorectal Neoplasms/surgery , Humans , Patient Selection , Prospective Studies , Retrospective Studies , SARS-CoV-2ABSTRACT
BACKGROUND: Distal pancreatectomy with celiac axis resection (DP-CAR) is a surgical procedure with high morbidity and mortality performed in patients with locally advanced pancreatic cancer. Preoperative embolization of hepatic artery (PHAE) has been postulated as a technical option to increase resection rate. OBJECTIVE: comparison of morbidity and mortality at 90 days, operative time, hospital stay and survival between patients that performed DP-CAR with and without PHAE. METHODS: Observational retrospective multicentre study. INCLUSION CRITERIA: patient operated in Spanish centers with DP-CAR for pancreatic cancer from April 2004 until 23 June 2018. Preoperative (PHAE, neodjuvant treatment), intraoperative (operative time and blood loss) and postoperative data (morbidity, hospital stay, R0 and survival) were studied. Complications were measured with Clavien classification at 90 days. Specific pancreatic complications were measured using ISGPS classifications. Data were analyzed using R version 3.1.3 (http://www.r-project.org). Level of significance was set at 0.05. RESULTS: 41 patients were studied. 26 patients were not embolized (NO-PHAE group) and 15 patients received PHAE. Preoperative BMI and percentage of neoadjuvant chemotherapy were the only preoperative variables different between both groups. The operative time in the PHAE group was shorter (343 min) than in the non-PHAE group (411 min) (p < 0.06). Major morbidity (Clavien > IIIa) and mortality at 90 days were higher in the PHAE group than in the non-PHAE group (60% vs 23% and 26.6% vs 11.6% respectively) (p < 0.004). No statistical difference in overall survival was observed between both groups (p = 0.14). CONCLUSION: In our study PHAE is not related with less postoperative morbidity. Even more, major morbidity (Clavien III-IV) and mortality was higher in PHAE group.
Subject(s)
Pancreatectomy , Pancreatic Neoplasms , Celiac Artery/surgery , Hepatic Artery/surgery , Humans , Pancreatic Neoplasms/surgery , Retrospective StudiesABSTRACT
OBJECTIVE: the aim of the study was to analyze the management of colorectal cancer (CRC) patients diagnosed with CRC or undergoing elective surgery during the period of the SARS-CoV-2 pandemic. MATERIAL AND METHODS: a multicenter ambispective analysis was performed in nine centers in Spain during a four-month period. Data were collected from every patient, including changes in treatments, referrals or delays in surgeries, changes in surgical approaches, postoperative outcomes and perioperative SARS-CoV-2 status. The hospital's response to the outbreak and available resources were categorized, and outcomes were divided into periods based on the timeline of the pandemic. RESULTS: a total of 301 patients were included by the study centers and 259 (86 %) underwent surgery. Five hospitals went into phase III during the peak of incidence period, one remained in phase II and three in phase I. More than 60 % of patients suffered some form of change: 48 % referrals, 39 % delays, 4 % of rectal cancer patients had a prolonged interval to surgery and 5 % underwent neoadjuvant treatment. At the time of study closure, 3 % did not undergo surgery. More than 85 % of the patients were tested preoperatively for SARS-CoV-2. A total of nine patients (3 %) developed postoperative pneumonia; three of them had confirmed SARS-CoV-2. The observed surgical complications and mortality rates were similar as expected in a usual situation. CONCLUSIONS: the present multicenter study shows different patterns of response to the SARS-CoV-2 pandemic and collateral effects in managing CRC patients. Knowing these patterns could be useful for planning future changes in surgical departments in preparation for new outbreaks.
Subject(s)
COVID-19 , Colorectal Neoplasms/surgery , Aged , Aged, 80 and over , Elective Surgical Procedures , Female , Humans , Male , Middle Aged , Prospective Studies , Retrospective Studies , SpainABSTRACT
BACKGROUND: Acellular pseudomyxoma peritonei (aPMP) is a rare peritoneal malignancy characterized by the accumulation of large amounts of mucin (lacking tumor cells) in the peritoneum. Many cases account for several kilograms of mucin to be screened by the pathologist. This is a comprehensive study of three patients with aPMP, whose tumors showed KRAS mutation, allowing for the tracking of this marker by liquid biopsy. METHODS: Pre and post-surgery plasma, and mucin removed during cytoreductive surgery were collected from the patients. KRAS mutations were analyzed using droplet digital polymerase chain reaction (ddPCR). Mucin was injected in mice. KRAS and cytokine levels were measured in plasma of the mice using ddPCR and a magnetic bead-based assay. Mucin microbiome was analyzed by 16S rRNA sequencing. RESULTS: KRAS mutations were detected in mucin cell-free DNA (cfDNA) from the three patients but not in the pre or post-surgery plasma. Electron microscopy detected microparticles (diameter <0.4 µm) in mucin. Mucin from one patient grew up inside the peritoneal cavity of mice and human KRAS was identified in mucin cfDNA, but not in plasma. All mucins showed the same bacterial profile. Cytokine levels were slightly altered in mice. CONCLUSIONS: The three aPMP patients included in this study shared some common aspects: the absence of tumor cells in mucin, the presence of KRAS mutated cfDNA in mucin, and the absence of this tumor-derived mutation in the bloodstream, providing additional information to the routine pathological examinations and suggesting that mucin cfDNA could potentially play a role in aPMP recurrence and prognosis.
ABSTRACT
BACKGROUND: Positive cytology has been identified as an independent negative prognostic factor in patients with peritoneal metastases (PM) of colorectal origin. Liquid biopsy in plasma may detect increasing levels of circulating tumor DNA (ctDNA) and could help predict systemic relapse in patients with colorectal cancer, but little is known about the role of liquid biopsy in peritoneal fluid. The aim of this study was to evaluate the prognostic value of peritoneal fluid and plasma liquid biopsy in patients undergoing complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CC-HIPEC). METHODS: A longitudinal prospective study was designed in patients with KRAS-mutated colorectal or appendiceal primary tumor, including PM of colorectal origin, pseudomyxoma peritonei and patients at high risk of developing PM (selected for second-look surgery). Eleven patients were recruited according to inclusion and exclusion criteria. ctDNA from plasma and peritoneal fluid before and after HIPEC was studied by droplet digital PCR looking for KRAS mutation. A close follow-up was scheduled (mean of 28.5 months) to monitor for systemic and peritoneal recurrences. RESULTS: All patients with positive plasma postHIPEC had systemic relapse and four patients died as a result, while those with negative plasma postHIPEC did not relapse. Patients with negative peritoneal ctDNA after CC-HIPEC did not present peritoneal relapse. Of six patients with positive peritoneal ctDNA postHIPEC, two presented peritoneal recurrence and four systemic relapses. CONCLUSIONS: Treatment with CC-HIPEC does not always neutralize ctDNA in peritoneal fluid, and its persistence after treatment may predict adverse outcome. Despite being a proof of concept, an adequate correlation between liquid biopsy in plasma and peritoneal fluid with both systemic and peritoneal relapse has been observed.
ABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , Breast Neoplasms/therapy , Carcinoma, Basal Cell/diagnosis , Neoplasms, Second Primary/diagnosis , Skin Neoplasms/diagnosis , Anilides/therapeutic use , Antineoplastic Agents/therapeutic use , Carcinoma, Basal Cell/drug therapy , Neoplasms, Second Primary/drug therapy , Pyridines/therapeutic use , Skin Neoplasms/drug therapy , Thoracic WallSubject(s)
Breast Neoplasms/therapy , Carcinoma, Basal Cell/diagnosis , Neoplasms, Second Primary/diagnosis , Skin Neoplasms/diagnosis , Aged , Anilides/therapeutic use , Antineoplastic Agents/therapeutic use , Carcinoma, Basal Cell/drug therapy , Female , Humans , Neoplasms, Second Primary/drug therapy , Pyridines/therapeutic use , Skin Neoplasms/drug therapy , Thoracic WallABSTRACT
El análisis citológico tiene un papel fundamental en el estudio de los nódulos tiroideos. Sin embargo, hasta un 30% de estos muestran citologías indeterminadas (Bethesda III o IV). En estos casos, se realizan cirugías diagnósticas que únicamente demuestran malignidad en un 15-35% de los pacientes. Se precisa una herramienta de mayor precisión para determinar la benignidad o malignidad del nódulo tiroideo con citología indeterminada sin precisar cirugías diagnósticas, evitando así posibles complicaciones y/o costes innecesarios. El uso complementario de paneles moleculares junto con la citología ha sido, de momento, la única herramienta que parece ayudar en este difícil escenario. Se realiza una revisión de la bibliografía sobre el estudio molecular complementario de los nódulos tiroideos para tratar de resumir las características intrínsecas de cada uno de los test disponibles, su coste-efectividad, y determinar sus indicaciones y su aplicabilidad en la práctica clínica habitual
Even though cytology remains the gold standard to assess the nature of thyroid nodules, up to 30% of the results are indeterminate (Bethesda III and IV). In these cases, current guidelines recommend performing diagnostic surgery, which proves malignancy in only 15-30% of cases. A more precise method is needed to avoid unnecessary surgeries, surgical complications and costs in the process of diagnosing indeterminate nodules. Complementary use of molecular profiling tests seems to help in this complex scenario. We present a review of the current literature on the usefulness of molecular profiling of thyroid nodules so as to define its indications, costs and usability for clinical practice
Subject(s)
Humans , Thyroid Nodule/diagnosis , Cell Biology , Cytological Techniques , Thyroid Neoplasms/diagnosis , Diagnosis, Differential , Thyroid Nodule/classification , Gene ExpressionABSTRACT
Even though cytology remains the gold standard to assess the nature of thyroid nodules, up to 30% of the results are indeterminate (BethesdaIII and IV). In these cases, current guidelines recommend performing diagnostic surgery, which proves malignancy in only 15-30% of cases. A more precise method is needed to avoid unnecessary surgeries, surgical complications and costs in the process of diagnosing indeterminate nodules. Complementary use of molecular profiling tests seems to help in this complex scenario. We present a review of the current literature on the usefulness of molecular profiling of thyroid nodules so as to define its indications, costs and usability for clinical practice.
Subject(s)
Thyroid Nodule/diagnosis , Thyroid Nodule/genetics , Humans , Molecular Diagnostic Techniques , Thyroid Nodule/pathologyABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , Acrospiroma/diagnosis , Acrospiroma/surgery , Breast Neoplasms/diagnosis , Breast Neoplasms/surgery , Sweat Gland Diseases/diagnosis , Sweat Gland Diseases/surgery , Immunohistochemistry , Early DiagnosisABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Colon/abnormalities , Colonoscopy , Anatomic Variation , Risk FactorsABSTRACT
Gastrointestinal duplications are unusual congenital malformations, nearly always diagnosed in childhood. Roughly 80% are cysts-like lesions and only a small percentage (4-18%) involves the colonic wall. Almost all are asymptomatic and therefore diagnosed as an incidental finding on imaging tests or when become complicated and present with perforation or bleeding. The need for an elective surgical treatment is controversial and should be indicated on an individual basis. This report is a case of an adult with a complete tubular colonic duplication found incidentally by colonoscopy that required surgical treatment due to perforation.
Subject(s)
Colon/abnormalities , Colon/diagnostic imaging , Colonoscopy , Colon/surgery , Female , Humans , Incidental Findings , Middle Aged , Tomography, X-Ray ComputedABSTRACT
Objetivos. Analizar la incidencia de recidiva locorregional y la evolución de las pacientes diagnosticadas de carcinoma infiltrante de mama con seguimiento de larga evolución. Métodos. Estudio retrospectivo de pacientes intervenidas por carcinoma infiltrante de mama entre enero de 2006 y diciembre de 2009. Criterios de inclusión: seguimiento mínimo de 24 meses, diagnóstico de recidiva locorregional de mama confirmado mediante biopsia. Se recogieron características diagnósticas y terapéuticas del tumor primario y la recidiva, la biología molecular, el tiempo libre de enfermedad y la supervivencia global a 5 años. Resultados. Cuatrocientas setenta y dos pacientes cumplieron los criterios de inclusión, con una mediana de seguimiento de 66 meses (47-85). Quince (3,2%) pacientes presentaron recaída locorregional. El diagnóstico fue carcinoma ductal infiltrante, la mediana del tamaño tumoral fue de 18 mm (12-30) y 16 mm en la recidiva (8-28). De las piezas analizadas, en 5 casos (2 luminal A, 2 luminal B y un HER2) la biopsia de la recidiva mostró un cambio histopatológico a triple negativo. Se observó un mayor índice de proliferación celular en la recidiva frente al tumor primario (45 vs. 30%; p = 0,068). La supervivencia libre de enfermedad en meses fue mayor en las pacientes con tumores que no eran triple negativo (33 vs. 28 meses; p = 0,199). Solo una paciente (6%) falleció a lo largo del periodo de seguimiento. Conclusiones. La incidencia de recidiva locorregional a 5 años permanece baja y dentro de los estándares actuales. La selección a triple negativo mostró peores tasas de supervivencia libre de enfermedad (AU)
Aims. To evaluate our results in locoregional recurrences in a cohort of patients with infiltrating breast cancer. Methods. A retrospective study was performed over patients with breast cancer who underwent surgery for breast cancer form January 2006 to December 2009 in Breast Surgery Unit of Fundación Jiménez Díaz University Hospital. Those with a minimum follow-up of 2 years and a locoregional recurrence confirmed by biopsy were selected. We analyzed patient and tumor's characteristics, time to recurrence confirmed by biopsy and long-term oncological outcomes. Results. 472 completed the inclusion criteria with a median follow-up of 66 months (47-85). Of them, 15 patients (3.2%) had a locoregional recurrence. A triple-negative breast cancer was found in 5 patients at the time of relapse (2 luminal A, 2 luminal B and one HER2), compared to one patient at the initial surgery. A higher cellular proliferation index was observed in recurrence tumors (45 vs. 30%; P = .068). Disease-free survival was higher in triple-negative non-selected patients (33 vs. 28 months; P = .199). During the follow-up period, one patient died (6%). Conclusions. In our experience, locoregional recurrence of breast cancer is low and similar to the existing standard guidelines. Patients with triple-negative selected tumors showed worst disease-free survival rates (AU)